Chutaro Akazawa obtains a license to operate a pharmacy

Permission to sell “rodent repellant” obtained, marking the beginning of the business in the field

A group of 212 companies in Kagawa Prefecture join together to establish “Kagawa Prefecture Pharmaceutical Co., Ltd”. and Chutaro Akazawa is appointed as the first president

Osaka Plant established in Higashi-yodogawa-ku (now Yodogawa-ku), Osaka

Osaka Plant spun off as “Fuso Chemical Co., Ltd.” and Shozo Akazawa is appointed president

Teikoku Seiyaku’s medicated plasters approved for prescription use, becoming the company’s main product line

“Teikoku Kampo Seiyaku Co., Ltd”. established New Shirotori Plant completed in Shirotori-cho (now Minato, Higashikagawa), Kagawa Prefecture

Teikoku Seiyaku acquires stock in Ohta Pharmaceutical Co., Ltd. and starts participating in management

“Catlep®”, Japan’s first transdermal indomethacin plaster for prescription use, approved and production begins
New plant (now Plant No.2), 5 stories and 6,451 square meters, completed at the site of headquarters complex

Company contributed to the Department of Pharmaco-Bio-Informatics, established at Kagawa Medical University (now Faculty of Medicine, Kagawa University)

Sales division spun off as an independent company, “Teikoku Medix Co., Ltd.”

Construction of Plant No.4 dedicated to manufacture of tapes and ointment completed
Ikeda Plant dedicated to manufacture of rodent poison begins operations in Ikeda-cho (now Miyoshi), Tokushima Prefecture (Transferred to Ikeda Yakusou Co., Ltd.)
“Seltouch®”, a transdermal felbinac plaster for prescription use, approved and production begins

Production begins at Tokushima Plant (Teikoku Kampo Seiyaku Co., Ltd.)

Non-prescription drug division (OTC) spun off as an independent company, “Teikoku Pharmacare Co., Ltd.”
Teikoku Seiyaku joins the Japan Pharmaceutical Manufacturers Association

Site of the former Sanbonmatsu Plant of Toyobo Co., Ltd., adjacent to Teikoku Seiyaku headquarters, acquired
US subsidiary, “Teikoku Pharma USA, Inc.”, established
Land adjacent to Tokushima Plant acquired and Donari Plant dedicated to manufacture of cosmetics and related products begins operations

“Lidoderm®”, the analgesic plaster for the treatment of post-herpetic neuralgia, approved and launched in the US

A morphine sulfate sustained-release capsule approved and production begins Production begins at new Plant No.7

“Fuso Teiyaku Qingdao Co., Ltd.”, established as a joint company by Teikoku Seiyaku Co., Ltd., Fuso Chemical Co., Ltd. and Qingdao Fuso Refining & Processing Co., Ltd.
New pharmacology building completed

160th anniversary of the founding of the business and 90th anniversary of the establishment of the company celebrated Teikoku Medix Co., Ltd. sold

Construction of a new warehouse completed next to the Tokushima warehouse

“Seltouch® Tape 70”, a felbinac tape for prescription use, approved and marketing begins in 2011
“Catlep® Tape 70mg” and “Catlep® Tape 35mg”, indomethacin tapes for prescription use, approved and marketing begins

Capital reduced to 100 million yen

A methadone hydrochloride tablet, approved and marketing begins in 2013

A fentanyl citrate buccal tablet co-developed with Taiho Pharmaceutical Co.,Ltd., approved and marketing begins
A oxycodone hydrochloride sustained-release capsule approved and marketing begins in 2014

Tokyo Office moved to Ogura Building located in Nihonbashi-kobunacho

Opened Higashi-Nihon Logistics Center in Higashi-Nihon MDC of Hitachi Logistics

Celebrated the one hundred and seventieth anniversary since foundation of the company and the one hundredth anniversary since incorporation

Seren Pharmaceuticals, Inc. becomes an affiliated company of Teikoku Seiyaku

Teikoku Seiyaku makes the Japanese Ministry of Economy, Trade and Industry’s 2020 Global Niche Top Companies Selection 100 List Receives Eruboshi certification. Eruboshi is awarded by the Ministry of Health, Labour and Welfare to employers who promote the participation and advancement of women in the workplace

Acquired manufacturing and marketing approval for Japan’s first Donepezil transdermal therapeutic system. ALLYDONE® 27.5 mg patches and ALLYDONE® 55 mg patches go on the market the following year

Achieves Kurumin mark certification as a childcare supportive organization